Touyun Biotech Group Limited released its monthly return (month ended 30 June 2026), showing no changes to either authorised or issued share capital.

Key share-capital details • Authorised share capital: 12.50 billion ordinary shares at HKD 0.04 par value, equal to HKD 500.00 million (unchanged). • Issued shares: 2.81 billion; treasury shares: nil (unchanged from the previous month).

Public float • The company affirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement as of 30 June 2026.

Share-option portfolio (no movements in June) 1. 0.60 million options, exercise price HKD 1.34 (granted 25 Apr 2022). 2. 60.20 million options, exercise price HKD 0.60 (granted 16 Nov 2020). 3. 77.70 million options, exercise price HKD 0.20 (granted 30 Sep 2024), of which 25.87 million shares remain available for future issuance.

Total shares that could be issued on full exercise of outstanding options: 86.67 million. No options were exercised, and no new shares were issued or repurchased during the month.

Governance confirmation Director Wang Liang signed the 3 July 2026 filing, confirming that all regulatory and listing-rule requirements related to share capital and option schemes have been met.